Biodexa announces appointment of precision for medicine llc as cro for european component of phase 3 study of erapa in fap

March 6, 2025 biodexa announces appointment of precision for medicine llc as cro for european component of phase 3 study of erapa in fap biodexa is finalizing plans to initiate an international phase 3 registrational study of erapa in familial adenomatous polyposis (fap) next quarter biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the appointment of precision for medicine, llc (“precision”) as the clinical research organization (“cro”) to conduct the european component of the upcoming registrational phase 3 study of erapa in fap. the u.s. component of the study will be conducted by lumabridge, based in san antonio, texas.
BDRX Ratings Summary
BDRX Quant Ranking